ZCCHC17 Antibody

What is ZCCHC17 and why is it significant in research?

ZCCHC17 (Zinc Finger CCHC-Type Containing 17) is a putative master regulator of synaptic gene expression that has been implicated in multiple disease pathways. It functions primarily as an RNA-binding protein involved in mRNA and rRNA processing . Recent evidence suggests ZCCHC17 coordinates a wide range of homeostatic functions in cells . The protein is particularly significant in neuronal function where it interacts with RNA splicing proteins and supports cognitive function . Additionally, ZCCHC17 has been identified as a potential biomarker in hepatocellular carcinoma, where it regulates immune cells in the tumor microenvironment .

What are the optimal applications for ZCCHC17 antibodies in experimental workflows?

ZCCHC17 antibodies have been validated for multiple experimental applications with varying specificities. Primary applications include:

• Western Blotting (WB): Most commercially available antibodies are optimized for WB with recommended dilutions typically around 1:1000 . This application allows detection of endogenous levels of ZCCHC17 protein, which has a molecular weight of approximately 27.6 kDa .

• Immunohistochemistry (IHC): Several antibodies have been validated for tissue localization studies .

• Flow Cytometry (FC): Some antibodies are suitable for analyzing ZCCHC17 expression in individual cells .

• Co-immunoprecipitation: FLAG-tagged ZCCHC17 constructs have been successfully used for co-IP followed by mass spectrometry to identify binding partners .

The choice of antibody should be based on the specific experimental goals and target species, as reactivity typically includes human, mouse, and rat samples .

How can researchers validate the specificity of ZCCHC17 antibodies?

Validation of ZCCHC17 antibodies should include:

• Knockdown/knockout controls: Compare antibody signals between wildtype samples and those with ZCCHC17 knockdown/knockout. Studies have used lentiviral shRNA approaches to reduce ZCCHC17 expression in neuronal cultures .

• Overexpression validation: Compare signals between control cells and those overexpressing tagged ZCCHC17 (e.g., FLAG-ZCCHC17). This approach has been documented using lentiviral-mediated expression of N-terminal or C-terminal FLAG-tagged ZCCHC17 .

• Western blot analysis: Verify band size corresponds to the expected molecular weight (approximately 27.6 kDa) .

• Cross-reactivity assessment: Test antibody specificity across multiple species if cross-species studies are planned. Many commercially available antibodies react with human, mouse, and rat ZCCHC17 .

• Peptide competition assays: For antibodies generated using synthetic peptides, competition with the immunogen peptide should abolish specific signals.

How does ZCCHC17 contribute to Alzheimer's Disease pathogenesis?

ZCCHC17 has been identified as a critical player in Alzheimer's Disease (AD) through several mechanisms:

• Early protein decline: ZCCHC17 protein levels decrease in AD brain tissue before significant gliosis or neuronal loss, suggesting it may be an early driver of pathology rather than a consequence .

• RNA splicing modulation: Co-immunoprecipitation followed by mass spectrometry analysis reveals that ZCCHC17 interacts with a network of RNA splicing proteins in human neurons . ZCCHC17 knockdown causes widespread RNA splicing changes that significantly overlap with splicing changes found in AD brain tissue .

• Synaptic gene regulation: ZCCHC17 acts as a master regulator of synaptic gene expression. When ZCCHC17 is reduced, expression of synaptic genes is dysregulated, which may contribute to synaptic dysfunction in AD .

• Cognitive resilience correlation: ZCCHC17 expression correlates with cognitive resilience in AD patients, suggesting it may have a protective role against cognitive decline .

• APOE4-dependent effects: Research has uncovered an APOE4-dependent negative correlation of ZCCHC17 expression with tangle burden, linking it to the major genetic risk factor for AD .

These findings collectively suggest that ZCCHC17 loss may be an important early driver of synaptic gene dysregulation and RNA splicing changes in AD pathogenesis.

What experimental approaches are most effective for studying ZCCHC17 in neuronal function?

Several experimental approaches have proven effective for investigating ZCCHC17's role in neuronal function:

• iPSC-derived neuronal models: Human induced pluripotent stem cell (iPSC)-derived neurons provide a relevant model system for studying ZCCHC17 function in human cells . These models allow for genetic manipulation and analysis of ZCCHC17's effects on neuronal development and function.

• Lentiviral-mediated expression/knockdown: Studies have used lentiviral vectors to either express tagged versions of ZCCHC17 (FLAG-ZCCHC17) or knock down ZCCHC17 using shRNA approaches . The detailed protocol typically includes:

  • Transfection of HEK293T cells with ZCCHC17 expression/knockdown constructs along with packaging plasmids (psPAX2, VSV-G)

  • Collection and concentration of viral particles

  • Infection of neuronal cultures with appropriate viral titers

  • Validation of expression/knockdown by Western blot or immunofluorescence

• RNA splicing analysis: RNA-seq followed by splicing analysis has been used to identify differential splicing events after ZCCHC17 knockdown . This approach reveals the broad impact of ZCCHC17 on neuronal RNA processing.

• Co-immunoprecipitation with mass spectrometry: This approach has identified ZCCHC17's binding partners in neurons, revealing its association with RNA splicing proteins . The protocol typically includes:

  • Infection of neurons with FLAG-tagged ZCCHC17

  • Cell lysis under conditions that preserve protein-protein interactions

  • Immunoprecipitation using anti-FLAG magnetic beads

  • Mass spectrometry analysis of co-precipitated proteins

• Immunohistochemistry: Characterization of ZCCHC17 expression patterns in brain tissue at varying antibody concentrations has revealed predominantly neuronal expression with strongest staining in the nucleolus of large pyramidal neurons .

How does ZCCHC17 knockdown affect synaptic protein expression?

ZCCHC17 knockdown in neuronal cultures has been shown to significantly impact synaptic protein expression through the following mechanisms:

• mRNA level changes: ZCCHC17 knockdown leads to decreased mRNA levels for multiple synaptic proteins, suggesting transcriptional or post-transcriptional regulatory effects .

• Protein level changes: Following ZCCHC17 knockdown, protein levels of multiple synaptic markers decrease, as demonstrated by both immunofluorescence and Western blot analysis .

• Differential effects on synaptic components: Not all synaptic proteins are affected equally. For example, studies have shown that Shank3 protein levels do not decline following ZCCHC17 knockdown, suggesting specificity in ZCCHC17's regulatory effects .

• Presynaptic vs. postsynaptic effects: Interestingly, some presynaptic markers (VGLUT and VGAT) show decreased mRNA levels following ZCCHC17 knockdown but maintain stable protein levels, highlighting the complex relationship between mRNA and protein regulation .

• Phenocopying of AD-related changes: The pattern of synaptic protein changes following ZCCHC17 knockdown resembles changes observed in Alzheimer's disease, supporting the hypothesis that ZCCHC17 loss contributes to AD pathophysiology .

These findings suggest that ZCCHC17 plays a critical role in maintaining proper expression of synaptic proteins, and its loss may contribute to synaptic dysfunction in neurodegenerative conditions.

What is the significance of ZCCHC17 expression in hepatocellular carcinoma?

ZCCHC17 has emerged as a potential biomarker in hepatocellular carcinoma (HCC) with several significant implications:

These findings collectively position ZCCHC17 as both a diagnostic and prognostic biomarker in HCC with potential therapeutic implications.

How does ZCCHC17 influence immune cell infiltration in the tumor microenvironment?

ZCCHC17 appears to play a significant role in regulating immune cell infiltration within the tumor microenvironment (TME) of hepatocellular carcinoma:

• Functional pathway enrichment: Gene Set Enrichment Analysis (GSEA) reveals that ZCCHC17 is significantly involved in multiple immune-related pathways, including:

  • Interactions between immune cells and microRNAs in the TME

  • Intestinal immune network for IgA production

  • PD-1 signaling

  • Cancer immunotherapy by PD-1 blockade

  • Immunoregulatory interactions between lymphoid and non-lymphoid cells

• Differential immune cell infiltration: Single-sample Gene Set Enrichment Analysis (ssGSEA) demonstrates that ZCCHC17 expression correlates with infiltration patterns of multiple immune cell types:

  Positive correlation with:

  • NK CD56bright cells (r=0.200, P<0.001)

  • T follicular helper cells (r=0.190, P<0.001)

  • Activated dendritic cells (r=0.190, P<0.001)

  • Th1 cells (r=0.100, P=0.048)

  • T helper cells (r=0.200, P<0.001)

  • Th2 cells (r=0.430, P<0.001)

  Negative correlation with:

  • Cytotoxic cells (r=0.180, P<0.001)

  • Th17 cells (r=0.210, P<0.001)

  • Plasmacytoid dendritic cells (r=0.190, P<0.001)

  • Dendritic cells (r=-0.180, P=0.001)

• Immune checkpoint gene correlation: ZCCHC17 expression positively correlates with multiple immune checkpoint genes, suggesting a role in immune escape mechanisms .

• Association with immunotherapy response predictors: ZCCHC17 expression positively correlates with tumor mutation burden (TMB) and microsatellite instability (MSI), both of which are predictors of immunotherapy response .

• TIDE score prediction: TIDE (Tumor Immune Dysfunction and Exclusion) analysis indicates that patients with high ZCCHC17 expression have significantly higher TIDE scores, predicting poorer response to immune checkpoint blockade therapy .

These findings suggest that ZCCHC17 may play an immunomodulatory role in HCC and could potentially influence the efficacy of immunotherapy in these patients.

What methodologies are recommended for analyzing ZCCHC17's role in cancer immune modulation?

To comprehensively analyze ZCCHC17's role in cancer immune modulation, researchers should consider the following methodological approaches:

• ssGSEA for immune cell infiltration analysis: Single-sample Gene Set Enrichment Analysis enables quantification of immune cell infiltration levels in tumor samples based on gene expression data . This method allows correlation of ZCCHC17 expression with specific immune cell populations.

• Correlation analysis with immune checkpoint genes: Spearman correlation analysis between ZCCHC17 expression and known immune checkpoint genes helps identify potential regulatory relationships .

• Tumor Immune Dysfunction and Exclusion (TIDE) analysis: TIDE computational framework predicts immunotherapy response by modeling mechanisms of tumor immune evasion. This approach can assess how ZCCHC17 expression affects predicted immunotherapy outcomes .

• Integrated bioinformatic analysis of TMB and MSI: Bioinformatic tools can quantify tumor mutation burden and microsatellite instability from genomic data, allowing correlation with ZCCHC17 expression .

• TP53 mutation status analysis: Chi-square test analysis of TP53 mutation status in relation to ZCCHC17 expression can reveal associations with this crucial tumor suppressor pathway .

• Flow cytometry validation: Flow cytometric analysis of tumor-infiltrating immune cells in experimental models with ZCCHC17 manipulation can validate computational predictions.

• Protein-protein interaction network analysis: Tools like STRING database can identify proteins interacting with ZCCHC17, revealing potential mechanisms of immune modulation .

• Gene Ontology (GO) and KEGG pathway enrichment analysis: These approaches identify biological processes, molecular functions, and pathways associated with ZCCHC17 expression .

These methodologies provide a comprehensive framework for investigating ZCCHC17's role in cancer immune modulation, combining computational analyses with experimental validation.

What are the optimal conditions for co-immunoprecipitation of ZCCHC17 and its binding partners?

Based on successful protocols in the literature, optimal conditions for co-immunoprecipitation of ZCCHC17 include:

• Expression system: Lentiviral-mediated expression of FLAG-tagged ZCCHC17 (either N-terminal or C-terminal tagging) has been successfully used in human iPSC-derived neurons . The tagging approach allows for:

  • Gateway cloning of ZCCHC17 into expression vectors (e.g., pLEX-305)

  • Lentiviral particle generation in HEK293T cells

  • Infection of target cells one week prior to immunoprecipitation

• Cell lysis conditions:

  • Cold IP lysis buffer supplemented with protease and phosphatase inhibitors

  • Incubation on ice for 15 minutes

  • Sample collection by scraping

  • Centrifugation at 12,000 × g for 10 minutes

• Immunoprecipitation parameters:

  • Anti-FLAG conjugated magnetic bead slurry (e.g., Sigma M8823)

  • Thorough washing of beads (6× with PBS) to remove glycerol

  • Sample dilution to appropriate volume with IP lysis buffer

  • Incubation at room temperature on a rotator for 2 hours

  • Magnetic separation and washing 2× with PBS

• Validation of co-immunoprecipitation:

  • Western blot analysis using antibodies against FLAG tag (1:1000, e.g., Sigma F3165)

  • Parallel detection of ZCCHC17 (1:1000, e.g., Abcam ab80454)

  • Detection of co-precipitated proteins (e.g., AP2A1, hnRNPU)

• Mass spectrometry analysis:

  • Sample preparation following standard proteomics workflows

  • Data analysis to identify significantly enriched proteins

  • Bioinformatic analysis of binding partners to identify functional clusters

This optimized protocol has successfully identified ZCCHC17's binding partners, revealing its interaction with a network of splicing proteins in human neurons.

How can researchers resolve discrepancies between mRNA and protein expression data for ZCCHC17?

Discrepancies between mRNA and protein expression data for ZCCHC17 are not uncommon and require careful methodological consideration:

• Technical validation approaches:

  • Use multiple antibodies targeting different epitopes of ZCCHC17

  • Compare results from different protein detection methods (Western blot, immunofluorescence, mass spectrometry)

  • Validate mRNA expression with multiple primers and normalization strategies

  • Include appropriate positive and negative controls in all experiments

• Biological explanations for discrepancies:

  • Post-transcriptional regulation: ZCCHC17 itself is an RNA-binding protein involved in RNA processing, so its own expression may be subject to complex post-transcriptional regulation

  • Protein stability differences: Changes in protein degradation rates may occur in disease states independent of mRNA changes

  • Cell type-specific expression: ZCCHC17 shows stronger expression in neurons than other cell types, so bulk tissue analysis may mask cell-type-specific changes

  • Subcellular localization changes: ZCCHC17 is present in both nucleus (particularly nucleolus) and cytoplasm, so changes in localization may affect detection efficiency

• Integrated analysis approaches:

  • Parallel analysis of both mRNA and protein from the same samples

  • Temporal studies to capture potential delays between mRNA and protein changes

  • Single-cell analysis to resolve cell type-specific differences

  • Analysis of both total and subcellular fraction samples

• Disease-specific considerations:

  • In Alzheimer's disease, ZCCHC17 protein decreases early in the disease process

  • In hepatocellular carcinoma, both mRNA and protein levels are elevated

  • These opposing patterns in different diseases suggest context-dependent regulation

When faced with discrepancies, researchers should avoid over-interpreting single measurements and instead integrate multiple lines of evidence with appropriate statistical analysis.

What are the key considerations for detecting ZCCHC17 in different subcellular compartments?

ZCCHC17 localizes to different subcellular compartments, presenting specific technical challenges for accurate detection:

• Subcellular distribution patterns:

  • ZCCHC17 predominantly localizes to the nucleus, with particularly strong staining in the nucleolus of neurons

  • At higher antibody concentrations, cytoplasmic staining is also observed

  • The pattern varies by cell type, with strongest expression in neurons compared to glial cells

• Immunohistochemistry optimization:

  • Antibody concentration affects detection pattern: lower concentrations (e.g., 1:1000) primarily detect nucleolar ZCCHC17, while higher concentrations reveal cytoplasmic localization

  • Fixation method impacts detection: 4% paraformaldehyde fixation for 20 minutes has been successfully used

  • Permeabilization is critical: 0.2% Triton X-100 in PBS for 5 minutes enables antibody access to nuclear ZCCHC17

  • Blocking conditions: 5% goat serum in PBS for 1 hour at room temperature reduces background

• Subcellular fractionation approaches:

  • Nuclear/cytoplasmic fractionation protocols should be optimized to preserve ZCCHC17 in both compartments

  • Western blot analysis of fractionated samples requires appropriate compartment-specific controls (e.g., Lamin B for nuclear fraction, GAPDH for cytoplasmic fraction)

• Immunofluorescence co-localization studies:

  • Nucleolar markers (e.g., fibrillarin, nucleolin) help confirm nucleolar localization

  • RNA processing body markers can identify potential cytoplasmic ZCCHC17 pools

  • High-resolution confocal microscopy with Z-stack imaging enhances detection accuracy

• Tagged constructs for live imaging:

  • FLAG-tagged constructs have been successfully used for ZCCHC17 detection

  • Both N-terminal and C-terminal tagging approaches have been validated

  • Viral expression systems allow efficient delivery to various cell types

These considerations help ensure accurate detection of ZCCHC17 across different subcellular compartments, providing insights into its function in various cellular processes.

How might ZCCHC17's splicing regulatory function be therapeutically targeted?

Given ZCCHC17's role in RNA splicing and its implications in diseases like Alzheimer's, several therapeutic targeting strategies merit exploration:

• Small molecule modulators:

  • Design of compounds that stabilize ZCCHC17 protein levels to counteract the decline observed in Alzheimer's disease

  • Development of inhibitors for specific ZCCHC17-protein interactions that might be pathologically enhanced in cancer contexts

  • Screening of molecules that can normalize the splicing patterns disrupted by ZCCHC17 loss

• RNA-based therapeutic approaches:

  • Antisense oligonucleotides (ASOs) targeting specific splicing events affected by ZCCHC17 loss

  • mRNA therapeutics to deliver functional ZCCHC17 to neurons in neurodegenerative conditions

  • microRNA modulators to influence ZCCHC17 expression levels

• Context-specific targeting strategies:

  • In neurodegenerative diseases: approaches to increase or stabilize ZCCHC17 expression

  • In hepatocellular carcinoma: strategies to reduce ZCCHC17 expression or interrupt its interaction with immune modulatory pathways

• Combination therapeutic approaches:

  • Pairing ZCCHC17-targeting strategies with immune checkpoint inhibitors in cancer contexts

  • Combining ZCCHC17 modulation with other approaches targeting RNA metabolism in neurodegeneration

• Biomarker-guided therapy selection:

  • Using ZCCHC17 expression levels to stratify patients for immunotherapy in HCC

  • Monitoring ZCCHC17-dependent splicing events as pharmacodynamic biomarkers for therapeutic efficacy

The development of these approaches requires overcoming significant challenges, including the need for cell-type-specific delivery systems and strategies to address potential off-target effects given ZCCHC17's broad involvement in RNA processing.

What are the methodological challenges in studying ZCCHC17's diverse functions across different tissues?

Studying ZCCHC17's diverse functions across tissues presents several methodological challenges:

• Cell type heterogeneity:

  • ZCCHC17 shows differential expression across cell types, with strongest expression in neurons

  • Single-cell approaches are needed to resolve cell-type-specific functions, particularly in complex tissues like brain

  • Bulk tissue analyses may mask important cell-type-specific changes

• Context-dependent functions:

  • ZCCHC17 appears to have opposing roles in different disease contexts - protective in neurodegeneration but potentially pathogenic in hepatocellular carcinoma

  • Systematic comparison across multiple tissues and disease models is needed to understand these divergent functions

  • Development of disease-specific experimental systems is required

• Technical limitations in splicing analysis:

  • Comprehensive detection of all splicing events affected by ZCCHC17 requires deep RNA sequencing

  • Validation of specific splicing events requires careful primer design and controls

  • Distinguishing direct from indirect effects on splicing is challenging

• Protein interaction dynamics:

  • ZCCHC17 interacts with numerous splicing factors and potentially other proteins

  • These interactions may be dynamic and context-dependent

  • Capturing these dynamics requires time-resolved interaction studies

• Translation to in vivo models:

  • Creating appropriate animal models that recapitulate human ZCCHC17 function

  • ZCCHC17 function appears conserved between species, but with potential differences

  • Balancing mechanistic studies in simplified systems with validation in complex in vivo environments

• Integration of multi-omics data:

  • Connecting ZCCHC17-mediated splicing changes to proteome alterations

  • Linking molecular changes to functional outcomes at cellular and organismal levels

  • Computational challenges in integrating diverse data types

Addressing these challenges requires multidisciplinary approaches combining advanced molecular techniques, computational methods, and disease-relevant model systems.

How can researchers best integrate ZCCHC17 data from both neurodegenerative and cancer research?

Integrating ZCCHC17 findings across neurodegenerative and cancer research requires systematic methodological approaches:

• Comparative molecular profiling:

  • Direct comparison of ZCCHC17 binding partners in neuronal versus cancer cell contexts

  • Analysis of splicing patterns affected by ZCCHC17 across different cellular backgrounds

  • Identification of common versus tissue-specific ZCCHC17 functions

• Unified bioinformatic frameworks:

  • Development of computational pipelines that can analyze ZCCHC17-related datasets from diverse disease contexts

  • Network biology approaches to identify common regulatory networks

  • Integration of publicly available datasets from both fields to increase statistical power

• Parallel experimental designs:

  • Implementation of identical ZCCHC17 manipulation approaches (e.g., knockdown, overexpression) across different cell types

  • Standardized assay conditions to allow direct comparison of results

  • Simultaneous testing in multiple disease models to control for experimental variation

• Mechanistic reconciliation strategies:

  • Identification of context-specific cofactors that may explain divergent functions

  • Analysis of post-translational modifications that might differ between contexts

  • Investigation of subcellular localization differences that could explain functional variations

• Translational integration approaches:

  • Examination of patient cohorts with comorbidities spanning both disease areas

  • Development of biomarker panels that incorporate ZCCHC17-related measurements

  • Consideration of potential therapeutic approaches that could have context-specific effects

• Collaborative research frameworks:

  • Establishment of cross-disciplinary research teams

  • Creation of shared resources and standardized protocols

  • Development of integrated data repositories

By systematically applying these approaches, researchers can develop a unified understanding of ZCCHC17 biology that spans traditional disease boundaries and potentially identifies novel therapeutic opportunities.